To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at <strong>{email}</strong> to confirm your account you can request a new one below. If you don't see it, you may need to <strong>check your spam</strong> folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you <strong>specific and relevant content</strong>

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, <b>Fotolia.de</b>, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

<strong>Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.</strong><br></br><br></br><br></br>

<strong>Please follow these steps to complete your registration:</strong><br></br><br></br>

<strong>Would you like to receive future text messages about Beyfortus updates?</strong>

<strong>Sanofi is here to help support your patients, their families, and caregivers.</strong><br></br><br></br>For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text.<br></br><br></br><strong>All fields are required.</strong>

Would you like to learn more about Beyfortus<sup>®</sup> (nirsevimab-alip) 50 mg and 100 mg injection?<br></br>Leave us your contact details, and a Sanofi representative will be in touch.<br></br><br></br><strong>All fields are required.</strong>

<strong>Would you also like to receive future messages and updates about Beyfortus?</strong>

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Request a visit from your local ALTUVIIIO representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Request a visit from your local QFITLIA representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX.<br></br><br></br>Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia.<br></br><br></br>Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required (unless otherwise specified).</strong>

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. <br></br>Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Step Ahead Sanofi website

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

integrated-diabetes-care

Integrated Diabetes Care

<h2>Low number of people with diabetes, using insulin, are achieving glycemic control</h2>

<p data-font="legal">*Target HbA1c &lt;7%; The IDMPS (N=1936) was a large, observational study program, collating data in seven individual waves from 2005 to 2017. The data from wave 7 (2016–2017) describing real-world acheivement of glycemic targets was reported in this study HCPs, Healthcare practitioners; OADs, oral antidiabetic drugs; T2DM, type 2 diabetes mellitus</p>

<h2>Once basal insulin has been initiated,&nbsp;titration inertia&nbsp;can become a predominant issue for people with diabetes</h2>

<p>Real-world evidence indicates that the structured and monitored titration algorithms that are applied in randomized controlled trials are not reflective of behavior in practice</p>

Reference

<h2>Fear of hypoglycemia&nbsp;is a major barrier to insulin initiation and optimal insulin titration</h2>
<p>Careful titration of insulin therapy can achieve glycemic control without a significant risk of hypoglycemia<sup>1</sup>; however, in clinical practice,&nbsp;<strong>fear of hypoglycemia is a common barrier</strong>&nbsp;to optimal titration, concordance and achieving glycemic targets with insulin<sup>1–3</sup></p>

<h2>Titration is a critical phase for basal insulin, and imperative for success of therapy</h2>
<p><strong>Difference in dose usage controlled Clinical Studies reality vs Real Life 45-75% of Basal&nbsp;</strong>T2 patients are uncontrolled and below optimal BI dose by as much as 30%.</p>

<p>Contact frequency determines outcome of basal insulin initiation trials.</p>

Titration Inertia; A Predominant Issue for People with Diabetes

INTEGRATED-DIABETES-CARE

DIABETES

Time-In-Range (TIR): How to interpret it and how it is associated with outcomes

<p>Watch the Interview with Dr. Richard Bergenstal, International Diabetes Center, Minneapolis, USA following the ATTD 2021 Congress. Dr. Richard Bergenstal explains on how to interpret TIR and how it is associated with outcomes.</p>

<h2>The burden associated with insulin self-management is high and&nbsp;People With Diabetes are responsible&nbsp;for most of their daily regimen</h2>

<p>HCP, healthcare professional; PWD, person with diabetes. Diabetes UK. Diabetes Education and Self-Management. Available at:<br><u><strong><a href="https://www.diabetes.org.uk/professionals/resources/shared-practice/diabetes-education#:~:text=Use%20the%20following%20resources%20and,year%20with%20a%20healthcare%20professional" target="_blank">https://www.diabetes.org.uk/professionals/resources/shared-practice/diabetes-education#:~:text=Use%20the%20following%20resources%20and,year%20with%20a%20healthcare%20professional</a></strong></u><strong>&nbsp;</strong>(last accessed September 2023)</p>

<h2>With this&nbsp;high burden&nbsp;on the individual with diabetes, concordance to insulin therapies remains low</h2>
<p>People with T2D may be likely to&nbsp;<strong>miss, mistime or reduce</strong>&nbsp;their basal insulin doses</p>

<p style="text-align: center;">A large proportion of missed or mistimed basal insulin doses were reported as&nbsp;<strong>unintentional</strong>,<br>
  whereas the majority of reduced basal insulin doses were reported as intentional</p>

<p data-font="legal">The GAPP2 study was an online multinational cross-sectional study of people with T2D currently treated with basal insulin (N=3,042), and HCPs involved in the care of such people. Basal insulin concordance patterns were evaluated with respect to three types of dosing irregularity: missed, mistimed [±2 hours from prescribed time], and reduced dose over the last 30 days. A total of 3,042 people with T2D treated with basal insulin analogs and 1,222 prescribers completed the full survey. GAPP2, Global Attitude of Patients and Physicians 2. Brod M, et al. Curr Res Med Opin 2012;28:1933–46.</p>

<h2>Multiple barriers&nbsp;exist to facilitate and maximize concordance to basal insulin therapy</h2>

The burden associated with insulin self-management

Type 2 Diabetes Cost Effective Management

<p>Prof. Colin Dayan discussing how to best manage your Diabetic Patients with a cost effective approach.</p>

World Diabetes Day

<p>Dr. Hussein Elbadawi talks about Hypoglycemia and how is it classified.</p>

Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management

<p>This engagement will address the unmet medical needs in diabetes quinary management through Multidisciplinary Team of top experts in the field of endocrinology and internal medicine in Gulf, India, Levant and Egypt.</p>

<h2>Patient Guide</h2>
<h3>Watch video guides to help your patients set up and use My Dose Coach App.</h3>
<p>Arabic videos can be available upon request. Please email: <a href="mailto:mydosecoach@mmscarabia.net"><u>mydosecoach@mmscarabia.net</u></a></p>

<h2>How do patients set up the My Dose Coach App</h2>

My Dose Coach - Patient Guide

<h2>How do patients use the My Dose Coach App every day<span>&nbsp;</span></h2>

<h2>How do patients enter a low blood sugar in the My Dose Coach App</h2>

<h2>Download My Dose Coach App for Patients</h2>
<p>Scan the QR code or click on the App Store Links or share the links with your patients to download My Dose Coach App.</p>

<h2>Get Started With My Dose Coach For HCPs</h2>
<p>&nbsp;<strong>Register in My Dose Coach Program through:</strong></p>
<ul>
 <li>Email:&nbsp;<a href="mailto:mydosecoach@mmscarabia.net"><u>mydosecoach@mmscarabia.net</u></a></li>
 <li>What’s App:&nbsp;<a href="tel:+966554673579"><u>+966554673579</u></a></li>
</ul>

<p><strong>For Technical Support, please contact call-center:</strong></p>
<ul>
 <li>Saudi Arabia - Toll Free Number 800 124 0226</li>
 <li>Kuwait - Phone Number +96 522 068960</li>
</ul>
<p>My Dose Coach is not intended to replace the care or advice of a healthcare team<br>
  My Dose Coach is approved in Saudi Arabia under authorization number: GHTF-2020-2084</p>

<h2>About My Dose Coach (MDC)</h2>
<h3>Empower Your Patients Taking Once Daily Long-Acting Basal Insulin To Self-Adjust Their Insulin Doses In Between Visits, With</h3>

<h2>How My Dose Coach Would Help You?</h2>

<p>My Dose Coach web portal allows you to easily prescribe and send a custom dose plan for your patients taking basal insulin.</p>

Prescribe a Dose Plan

black

<p>Your patient needs to record their daily fasting blood glucose readings and insulin dose administered in the My Dose Coach app to start getting insulin dose recommendations based on your prescribed dose plan.</p>

Help Your Patient Stay On Track With Their Insulin Dose Plan

<p>You can review your patient’s blood glucose and insulin dose data in the My Dose Coach web portal to follow your patient’s progress.</p>
<p>My Dose Coach May Enhance Communication Between You and Your Patients</p>

Manage and Monitor Your Patient’s Dose Plan

<h2>How My Dose Coach Would Help Your Patients?</h2>

<p>1. Patients check and record their fasting blood glucose as often as directed by you.</p>

<p>2. Patients check the app at the time of injection to receive insulin dose recommendations.</p>

<h2>With My Dose Coach App, Patients Can:</h2>

<p>1. Track their blood glucose levels and insulin doses in the “History” section; or consult their dose plan in the “Summary of instructions”.</p>

<p>2. Find helpful resources on how to manage basal insulin therapy and use My Dose Coach app successfully.</p>

Register your clinic in My Dose Coach HCP Platform

My Dose Coach - About MDC

<h2>Effectiveness of myDose Coach&nbsp;MDC-assisted basal insulin titration in People with Type 2 Diabetes in Saudi Arabia and Kuwait*</h2>

<h3>Results</h3>
<div>
 <table border="1" cellpadding="1" cellspacing="1" style="width:100%;">
  <tbody>
   <tr>
    <td>
     <p>Among PWT2D in&nbsp;<strong>Saudi Arabia and Kuwait</strong>, use of My Dose Coach™&nbsp;with Toujeo led to a&nbsp;<strong>Better Glycemic Control with Low Risk of Hypoglycemia;</strong></p>
     <p>The best glycemic outcomes were observed with high versus moderate or low usage of the app</p></td>
   </tr>
  </tbody>
 </table>
</div>

<h2>cBGM Integration - Pairing Process</h2>

<h2>cBGM Integration – Automated BG data entry</h2>

Integrated Diabetes Care

Latest Articles